Gilead-WHO for Leishmaniasis

Committed to support the global effort to control and eliminate visceral leishmaniasis.

Gilead-WHO for Leishmaniasis

Gilead has a Memorandum of Understanding (MoU) with the World Health Organization (WHO) to provide AmBisome® (liposomal amphotericin B) at no profit to developing world countries for the treatment of mucosal and visceral leishmaniasis. It is estimated that visceral leishmaniasis affects 500,000 people annually, with the number of deaths ranging from 60,000 to 200,000. The majority of cases occur in Bangladesh, Nepal, India, Brazil, and Sudan.


  • Gilead

    Goods Supplier
    United States | Staff size: 501-1000

    Gilead Sciences was founded in 1987 in Foster City, California. In 25 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of...

  • World Health Organization (WHO)

    Funding Agencies
    Staff size: 5001-10,000

    WHO (World Health Organisation) is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters,...

More Resources

Key Information

LocationSouth Asia, Sudan, India, Brazil, Bangladesh, North Africa and Middle East, Latin America and Caribbean
  • Start Date 2011
  • End Date 2016
  • ValueUSD 8 Million